LacriJet® is FCI latest and exclusive 1st preloaded & self-retaining monocanalicular nasolacrimal intubation indicated for epiphora, congenital nasolacrimal duct obstruction and canalicular laceration.
Ritleng®+ is FCI latest autostable bicanalicular nasolacrimal intubation indicated for epiphora, canalicular pathologies, congenital lacrimal duct obstruction and dacryocystorhinostomy (DCR).
"Tearing and conjunctivitis in children are commonly due to lacrimal drainage system obstruction. Congenital nasolacrimal obstruction is a common pathology treated by probing with or without silicone stent insertion, depending upon the age of the child. The silicone stent is self-retaining and placed for at least one month. Masterka® is a recent version of Monoka®, which may lead to the same surgical complications, such as intralacrimal migration."
Journal Français d'Ophtalmologie, Volume 41, Issue 3, March 2018, Pages 206-211